A Confirmed Partial Response in GEJ Patient, Stable Disease demonstrated in 75% of patients with mutated-KRAS colon cancer
REHOVOT, Israel, May 27, 2022 (GLOBE NEWSWIRE) — Purple Biotech Ltd. (“Purple Biotech”, or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company focused on developing first-in-class, effective and durable therapies by harnessing the power of the tumor microenvironment to overcoming tumor immune evasion and drug resistance, today announced positive interim safety and efficacy data from the Phase 1 study of NT219 in adults with advanced solid tumors. Findings will be presented during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting as a poster presentation during the Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology track (Abstract #3096).
“We are very encouraged by the initial safety and efficacy signals from NT219, and the durability of response,” said Michael Schickler, Ph.D., Head of Clinical & Regularly Affairs at Purple Biotech. “One patient with refractory gastroesophageal junction cancer, previously treated with four prior lines of therapies, was treated for 22 weeks and achieved a confirmed partial response. Remarkably, the patient has not progressed, approximately one year after the end of treatment. This, together with the demonstrated stable disease for patients with mutated-KRAS colon cancer and with the preclinical studies of NT219 in this cancer…
